Outcome in Klaria’s rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN KLARIA. SEE THE "IMPORTANT INFORMATION" SECTION BELOW.
Klaria Pharma Holding AB ("Klaria" or "the Company"), today announced the outcome of the rights issue with preferential rights for the shareholders (the “Rights Issue") that ended on December 21, 2022. The subscription breakdown shows that approximately 33.5 percent was subscribed with and without the exercise of subscription rights. Consequently, underwriters of the Rights Issue will be allocated approximately 46.5 percent of the Rights Issue thus resulting in that Klaria obtains SEK 59.2 million before issue costs. Those who have been allocated shares without the support of subscription rights will be notified by contract note alternatively through their nominee.
The subscription period for the Rights Issue ended on December 21, 2022 and the summary shows that 19,211,751 shares, corresponding to approximately 32.5 percent, were subscribed for by the exercise of subscription rights. In addition, the Company received interest from investors of subscribing an additional 637,924 shares without the support of subscription rights, corresponding to approximately 1.1 percent for a total subscription with and without the exercise of subscription rights of 33.5 percent. Consequently, underwriters of the Rights Issue will be allocated 46.5 percent of the Rights Issue, distributed approximately 14.9 percent to the top guarantors, 13.5 percent to the middle guarantors and 18.1 percent to the bottom guarantors. Klaria obtains SEK 59.2 million before issue costs. Notification of allotment of shares subscribed for without exercising subscription rights will shortly be sent to those who have been allotted shares via contract note. Nominee shareholders receive notification of allotment in accordance with the respective nominee's routines. Allocation of shares subscribed for without the exercise of subscription rights has been carried out in accordance with the principles stated in the prospectus that was published on December 2, 2022.
"We are delighted to have secured financing for Klaria through 2023, which will be the most important and transformative year in the Company's history. We have submitted an application for market approval with our lead product, a milestone many biotech companies never reach. , Now we enter 2023 with a strengthened balance sheet and the support of several new long-term investors. We thank our existing and new shareholders who, despite a troubled and turbulent environment, are supporting Klaria in this exciting phase. In addition to the fact that next year we can get approval to launch our first drug, Klaria has a strong pipeline with three partnered programs, which means that we can look towards the future with confidence.. This capital injection provides Klaria with the necessary funds to develop the company in the right direction”, says Jesper Wiklund, CEO Klaria
Share capital and number of shares
After the Rights Issue is registered with The Swedish Companies Registration Office the Company’s share capital will increase with approximately SEK 796,226.114 to approximately SEK 1,791,508.749. The number of shares will increase with 47,333,566 shares to 106,500,523 shares.
Trading in BTA
Trading in paid subscribed shares (“BTA”) will take place on Nasdaq First North Growth Market until the week after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration of the Rights Issue is expected to take place during week 2, 2023.
Advisors
In connection with the Rights Issue, Klaria has engaged Erik Penser Bank AB and Setterwalls Advokatbyrå AB as financial and legal advisers.
For more information, please contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
Tel: +46 (0) 8-446 42 99
This information is information that Klaria obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on December 22, 2022 19:45 CEST.
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor ([email protected], +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.
Important information
The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Klaria. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Klaria will only take place through the prospectus that Klaria:s published December 2, 2022.
The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Klaria have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.
Forward-looking statements
This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.
Such risks, uncertainties, contingencies, and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.
